{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:22Z","timestamp":1790262142097,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing complexity and diversity of innovative drug clinical trials in China have expanded the competencies expected of principal investigators (PIs) beyond minimum regulatory qualifications. However, existing frameworks are primarily international and may not fully reflect China's institutional and regulatory context. This study aimed to develop a concise PI competency inventory adapted to China and to explore a differentiated, context-sensitive approach to competency development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multiphase mixed-methods modified Delphi study was conducted. First, an initial pool of 64 competency indicators was generated through a structured literature review and semi-structured expert interviews. Subsequently, two rounds of the Delphi method were conducted. In the initial round, a comprehensive expert recruitment process was undertaken, leading to indicator integration through quantitative correlation and content analyses which streamlined the indicators to 30 items. The second-round consultation was conducted using the streamlined indicators.Panel composition changed between rounds: some Round 1 experts did not participate in Round 2, and two regulatory experts were added to strengthen stakeholder representation and content validity. The Statistical Package for the Social Sciences (SPSS) 26.0 was utilized for quantitative analysis, encompassing descriptive statistics, the calculation of Kendall's\n                      <jats:italic>W<\/jats:italic>\n                      and the coefficient of authority (Cr).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An exploratory framework comprising 30 competencies was established. The mean expert authority coefficient was 0.87. The test of concordance was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), but Kendall's\n                      <jats:italic>W<\/jats:italic>\n                      was 0.206, indicating limited inter-expert concordance. Indicators were categorized into three descriptive strata by coefficient of variation (CV): high-consensus (CV\u2009\u2264\u20097%; 4 items), medium-consensus (7%\u2009&amp;lt;\u2009CV\u2009\u2264\u200917%; 19 items), and low-consensus (high-divergence) (17%\u2009&amp;lt;\u2009CV\u2009&amp;lt;\u200925%; 7 items). These strata describe variability in the panel's ratings and do not establish differences in competency importance or a developmental sequence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This exploratory 30-item inventory provides an initial structure for evaluating PI competencies in China's innovative-drug trial context. Its differentiation logic offers preliminary perspectives to inform the future development of differentiated and context-sensitive PI competency models. While this framework may inform future training system design, institutional human-resource management, and PI career development, its long-term validity, feasibility, and practical utility warrant prospective, real-world evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1933721","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:54:46Z","timestamp":1790142886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond GCP: developing a differentiated competency framework for principal investigators in innovative drug clinical trials in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Bo","family":"Sun","sequence":"first","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiling","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Center, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Dong","sequence":"additional","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meicheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Center for Drug Evaluation and Inspection","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","author":"Barwick","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/cpt.70099","article-title":"Cell and gene therapy product approvals in China: insights into clinical trials and regulatory advances","volume":"118","author":"Huang","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"B3","year":"2026"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1017\/cts.2025.105","article-title":"Unlocking potential: introducing the PI badge, a micro-credential for clinical trial investigators","volume":"9","author":"Jose","year":"2025","journal-title":"J Clin Transl Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1111\/cts.70117","article-title":"Decentralized clinical trials in the era of real-world evidence: a statistical perspective","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Transl Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12916-024-03712-4","article-title":"Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review","volume":"22","author":"Jeffers","year":"2024","journal-title":"BMC Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10452-022-01354-9","article-title":"Gene and cell therapies in China: booming landscape under dual-track regulation","volume":"15","author":"Yin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B8","volume-title":"ICH Harmonised Guideline: Integrated Addendum to ICH E6(R3): Guideline for Good Clinical Practice (GCP)","year":"2025"},{"key":"B9","volume-title":"Good Clinical Practice for Drug Clinical Trials (Order No. 57 of 2020)","year":"2020"},{"key":"B10","year":"2023"},{"key":"B11","volume-title":"Investigator Responsibilities\u2014Protecting the Rights, Safety, and Welfare of Study Subjects: Guidance for Industry","year":"2024"},{"key":"B12","volume-title":"E6(R3) Good Clinical Practice (GCP) Guidance for Industry","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1291675","DOI":"10.3389\/fphar.2024.1291675","article-title":"Education and training of clinical research professionals and the evolution of the joint task force for clinical trial competency","volume":"15","author":"Sonstein","year":"2024","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s43441-024-00680-x","article-title":"Research on core competency elements of clinical investigators","volume":"59","author":"Wang","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1578955","DOI":"10.3389\/fphar.2025.1578955","article-title":"Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal","volume":"16","author":"Bogas","year":"2025","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e000229","DOI":"10.1136\/bmjgh-2016-000229","article-title":"Developing a globally applicable evidence-informed competency framework to support capacity strengthening in clinical research","volume":"2","author":"Jul\u00e9","year":"2017","journal-title":"BMJ Glob Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105918","DOI":"10.1016\/j.cct.2019.105918","article-title":"Improving the quality conduct and efficiency of clinical trials with training: recommendations for preparedness and qualification of investigators and delegates","volume":"89","author":"Bechtel","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3969\/j.issn.1009-0959.2024.02.021","article-title":"Essential abilities and requirements for drug clinical trial investigators based on legal and regulatory frameworks","volume":"26","author":"Jiang","year":"2024","journal-title":"Chin J Med Guide"},{"key":"B19","volume-title":"ACRP Functional Competency Guidelines for Principal and Sub-Investigators\u2122","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1017\/cts.2016.2","article-title":"Education and training of clinical and translational study investigators and research coordinators: a competency-based approach","volume":"1","author":"Calvin-Naylor","year":"2017","journal-title":"J Clin Transl Sci"},{"key":"B21","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/cts.2016.3","article-title":"Best practices in social and behavioral research: report from the enhancing clinical research Professional's Training and qualifications project","volume":"1","author":"Murphy","year":"2017","journal-title":"J Clin Transl Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.31486\/toj.19.0085","article-title":"Investigator responsibilities in clinical research","volume":"20","author":"Feehan","year":"2020","journal-title":"Ochsner J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/2168479017743122","article-title":"Research misconduct in FDA-regulated clinical trials: a cross-sectional analysis of warning letters and disqualification proceedings","volume":"52","author":"Garmendia","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"B25","year":""},{"key":"B26","volume-title":"Measures for the Supervision and Inspection of Drug Clinical Trial Institutions (Trial) (Announcement No. 56 of 2023)","year":"2023"},{"key":"B27","volume-title":"Provisions for the Administration of Drug Clinical Trial Institutions (Announcement No. 101 of 2019)","year":"2019"},{"key":"B28","year":""},{"key":"B29","volume-title":"Designing and Conducting Mixed Methods Research","author":"Creswell","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3870\/j.issn.1004-0781.2026.03.017","article-title":"Research method in pharmaceutical practice: an integrated perspective review of qualitative, quantitative and mixed methods","volume":"45","author":"Yin","year":"2026","journal-title":"Herald Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e110217","DOI":"10.1136\/bmjopen-2025-110217","article-title":"Construction of emergency nursing-sensitive quality indicator system for patients with severe trauma: a modified Delphi study in Chinese context","volume":"16","author":"Xie","year":"2026","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fpubh.2018.00149","article-title":"Best practices for developing and validating scales for health, social, and behavioral research: a primer","volume":"6","author":"Boateng","year":"2018","journal-title":"Front Public Health"},{"key":"B35","volume-title":"Adaptive Evolution of Business Models in the Context of China's Transitional Economy: Motivation, Mechanism and Effect","author":"L\u00fc","year":"2016"},{"key":"B36","volume-title":"Modern Epidemiology Methods and Application","author":"Zeng","year":"1994"},{"key":"B37","doi-asserted-by":"publisher","first-page":"tkab046","DOI":"10.1093\/burnst\/tkab046","article-title":"Consensus on the health education of home-based negative pressure wound therapy for patients with chronic wounds: a modified Delphi study","volume":"9","author":"Huang","year":"2021","journal-title":"Burns Trauma"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.4324\/9781003293491","volume-title":"Applied Multivariate Statistical Concepts","author":"Hahs-Vaughn","year":"2024"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1933721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:07:20Z","timestamp":1790258840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1933721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1933721"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1933721","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1933721"}}